DE&I

April 16, 2024 Alnylam Ranked #3 on LinkedIn's List of Top Midsize Companies for 2024 Alnylam is proud to be included on LinkedIn's Top Companies list for 2024. Read More ›
February 29, 2024 Alnylam Named to Human Rights Campaign’s Corporate Equality Index Alnylam has achieved a score of 90 out of 100 on the Human Rights Campaign's (HRC) 2023-2024 Corporate Equality Index (CEI) based on our US policies, practices, Read More ›
July 24, 2023 Alnylam Named a Best Workplace for Millennials for 2023 by Fortune and Great Place to Work Alnylam is ranked #19 on Fortune and Great Place to Work's 2023 list of Best Workplaces for Millennials. Read More ›
March 29, 2023 Leading by Example in Gender Diversity Among Executive Leadership Alnylam ranked #1 among MA public companies in board of directors gender diversity and #3 in executive leadership gender diversity in the 2023 WPG report.   Read More ›
January 31, 2023 Alnylam Named to Bloomberg's Gender-Equality Index for 3rd Year in a Row Alnylam has been named to Bloomberg's Gender Equality Index (GEI) for the 3rd year in a row. Read More ›
November 30, 2022 Alnylam Named #1 Largest Employer in MA for 2nd Year in a Row by The Boston Globe Alnylam is a Boston Globe Top Place to Work for the 8th consecutive year and the #1 ranked company on the "Largest Employers" list for the second year in a row Read More ›
September 27, 2022 Alnylam Named a Best Workplace for Women by Fortune Magazine Alnylam has been named a Fortune Best Workplace for Women for 2022 Read More ›
March 16, 2022 Alnylam Publishes 2021 Corporate Responsibility Report We're committed to taking bold actions that improve the health of humanity. Our 2021 Corporate Responsibility Report provides details on our progress... Read More ›
February 28, 2022 Supporting Health Equity for All Through Leadership, Action and Partnership "Health equity" means that everyone has a fair and just opportunity to live the healthiest life possible, regardless of who they are, where they live or how... Read More ›
January 26, 2022 Alnylam Named to Bloomberg's Gender-Equality Index for 2nd Year in a Row Alnylam has been named to Bloomberg's 2022 Gender-Equality Index (GEI) - an important diversity, equity and inclusion benchmark, for the 2nd year in a row. Read More ›

You are now leaving Alnylam.com

The following content may not be associated with Alnylam Pharmaceuticals.

Links to all outside sites are provided as a reference for our visitors.

Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site